NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds investors that a shareholder filed a class action lawsuit on behalf of purchasers of common stock of Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) between May 12, 2022 and September 22, 2022, both dates inclusive (the "Class Period†). The lead plaintiff process was reopened by the Court. Spectrum Pharmaceuticals describes itself as a "biopharmaceutical company focused on acquiring, developing, and commercializ. ...

In this article, we will be taking a look at the Top 10 AI-Powered Biotech Stocks to Buy Now. AbbVie Inc. stands second among them. AbbVie Inc. (NYSE:ABBV), a global biopharmaceutical leader known for therapies across immunology, oncology, and neuroscience, recently secured a major development for its immunology portfolio. On September 11, 2025, the company announced a settlement with all generic manufacturers challenging Rinvoq (upadacitinib), extending its U.S. patent protection and exclusivity until 20 ...

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) is among the best fundamentally strong penny stocks to buy right now. According to the recent Form 13F filing with the SEC, Acadian Asset Management LLC expanded its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) by 25.9% in the first quarter. With the purchase of 451,044 shares, the investment manager now owns 2,195,191 shares of the company’s stock, representing an ownership stake of 2.03%. Despite the company’s history of failures, Aclaris Therapeutics, In ...

Benzinga and Yahoo Finance LLC may earn commission or revenue on some items through the links below. Bristol-Myers Squibb Co. (NYSE:BMY) is an American multinational biopharmaceutical company that develops, manufactures, and markets innovative medicines to help patients with serious diseases. It will report its Q3 2025 earnings on Oct. 30. Wall Street analysts expect the company to post EPS of $1.67, down from $1.80 in the prior-year period. According to data from Benzinga Pro, quarterly revenue is expect ...

Cemsidomide in Combination With Dexamethasone Achieved a 50% Overall Response Rate (ORR) at the Highest Dose Level (100 µg) and a 40% ORR at the 75 µg Dose Level in a Heavily Pre-Treated Relapsed/Refractory Multiple Myeloma Patient Population Responses Across Dose Levels With Median Duration of Response of 9.3 Months as of the Data Cut-off Date; Median Duration of Response Not Yet Reached at Two Highest Doses No Discontinuations Related to Cemsidomide and Few Dose Reductions Support a Safety Profile That Ma ...

Savara Inc. (NASDAQ:SVRA) is one of the best healthcare penny stocks to buy now. On September 9, Guggenheim raised its price target of the stock to $11 from $8 while reiterating a Buy rating. The price target hike follows an impressive 16% stock rally year to date. Guggenheim Lifts Savara (SVRA) Price Target on Pulmonary Alveolar Proteinosis Opportunity The research firm raised its price target, buoyed by positive developments that affirm long-term prospects. For starters, the company has achieved alignm ...

NEW YORK, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at Bernstein’s 2nd Annual Healthcare Forum on Tuesday, September 23, 2025 at 2:50 p.m. ET. The webcast will be accessible from Royalty Pharma’s “Events” page at https://www.royaltypharma.com/investors/events/. The webcast will also be archived for a minimum of thirty days. About Royalty Pharma Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical roy ...

CARMEL, Ind., Sept. 19, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it will provide topline results from its Phase 2 clinical trial of potential once-weekly canvuparatide for patients with chronic hypoparathyroidism (HP) and host an investor webcast on Monday, September 22. The Company will host ...

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), September 19, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced its decision to discontinue its VS-01 program in ACLF (Acute-on-Chronic Liver Failure), and reprioritize the development of VS-01 on UCD (Urea Cycle Disorder). GENFIT’s decision follows the occurrence of a peritonitis case reported as Seri ...

SAN DIEGO, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds stockholders that a class action was filed on behalf of persons and entities that purchased or otherwise acquired Cytokinetics, Inc. (NASDAQ: CYTK) securities between December 27, 2023 and May 6, 2025. Cytokinetics is a biopharmaceutical company focused on discovering, developing, and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performan ...